## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound of formula (IE) or a salt, N-oxide, hydrate or solvate thereof, for use in human or veterinary medicine:

$$\begin{array}{c|c} R_1 & R_3 \\ \hline & A & \\ & & \\$$

wherein

ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms:

 $R_1$  is attached to a first ring atom of ring A and is a group of formula (IAII):

$$Q_{-(Alk^2)_s-(Z)_{r^-}(Alk^1)_p} \xrightarrow{R} \qquad \qquad (II)$$

 $-\Lambda r^{\dagger}$   $-(\Lambda lk^{\dagger})_p$   $-(Z)_r$   $-(\Lambda lk^2)_s$  -Q  $-(I\Lambda)$ 

wherein in any compatible combination

Ar1 is an optionally substituted aryl or heteroaryl radical,

 $Alk^1$  and  $Alk^2$  are optionally substituted divalent  $C_1\text{-}C_6$  alkylene or  $C_2\text{-}C_6$  alkenylene radicals,

p, r and s are independently 0 or 1,

 $\label{eq:Zis-O-,-S-,-(C=O)-,-(C=O)-,-NR^A-,-C(=O)NR^A-,-C(=O)NR^A-,-C(=O)NR^A-,-NR^AC(=O)-,-NR^ASO_2- or -NR^A- wherein R^A is hydrogen or C_1-C_6 alkyl, and$ 

Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical, and R represents hydrogen or one or more substituents selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, hydroxy, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, mercapto, mercapto(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, -COOH, -COOR<sup>A</sup>, -COR<sup>A</sup>, -SO<sub>2</sub>R<sup>A</sup>, -CONH<sub>2</sub>, -SO<sub>2</sub>NH<sub>2</sub>, -CONHR<sup>A</sup>, -SO<sub>2</sub>NHR<sup>A</sup>, -CONR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NR<sup>A</sup>R<sup>B</sup>, -NH<sub>2</sub>, -NHR<sup>A</sup>, -NR<sup>A</sup>R<sup>B</sup>, -OCONH<sub>2</sub>, -OCONHR<sup>A</sup>, -OCONR<sup>A</sup>R<sup>B</sup>, -NHCOOR<sup>A</sup>, -NHCOOR<sup>A</sup>, -NR<sup>B</sup>COOR<sup>A</sup>, -NHSO<sub>2</sub>OR<sup>A</sup>, -NR<sup>B</sup>SO<sub>2</sub>OR<sup>A</sup>, -NHCONH<sub>2</sub>, -NHCONHR<sup>B</sup>, -NHCONR<sup>B</sup>, -NHCONR<sup>A</sup>R<sup>B</sup>, wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>6</sub>)alkyl group.

R2 is attached to a second ring atom of ring A, which is adjacent the first ring atom to which R<sub>1</sub> is attached, or is absent if that ring atom is a nitrogen atom which is double bonded to a neighboring ring atom, and if not absent R<sub>4</sub> is hydrogen or

- (i) a group of formula (IA) as defined in relation to  $R_1$ ; .
- (ii) a carboxamide radical; or
- (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk¹)<sub>p</sub>-(Z)<sub>r</sub>(Alk²)<sub>s</sub>-Q wherein Q, Alk¹, Alk², Z, p, r and s are as defined above in relation to group (IA): and

 $R_3$  is attached to a third ring atom of ring  $\Lambda$ , which is adjacent the second ring atom to which  $R_2$  is attached, or is absent if that ring atom is a nitrogen atom which is double bonded to a neighboring ring atom, and if not absent  $R_2$  is hydrogen, optionally substituted cycloalkyl, cycloalkenyl,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl, or  $C_2$ - $C_6$ alkynyl; or a carboxyl, carboxamide or carboxyl ester group,

PROVI DED THAT (a) at least one of  $R_2$  and  $R_3$  is present and is other than hydrogen-and (b) the compound of formula (I) is not one of formula (IA) (IB)<sub>2</sub> (IC) or (ID)

wherein  $R_4$ ,  $R_2$  and  $R_3$  are as defined above, and R is hydrogen or optionally substituted  $C_4$ - $C_6$  alkyl.

- (Canceled)
- 3. (Canceled)
- 4. (Canceled)
- 5. (Canceled)
- 6. (Canceled)
- 7. (Canceled).
- 8. (Currently Amended) The compound as claimed in claim 1 wherein in the group  $R_1$  of the compound of formula (IE) each of p, r and s is 0, and Q is hydrogen.

- (Previously Presented) The compound as claimed in claim 8 wherein R<sub>1</sub> is 2hydroxyphenyl optionally further substituted by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy, chloro, or bromo.
- (Currently Amended) The compound as claimed in claim 1 wherein in the eempound of formula (I)-R<sub>1</sub> has formula (IIA):

wherein R represents bromo, chloro, phenyl, C<sub>1</sub>-C<sub>6</sub> alkyl or phenyl(C<sub>1</sub>-C<sub>6</sub> alkyl)-.

- 11. (Withdrawn Currently Amended) The compound as claimed in claim 1 wherein in the group  $R_1$  of the compound of formula (IE) one or more of p, r and s is 1.
- 12. (Withdrawn) The compound as claimed in claim 11 wherein p and/or s is/are 1 and r is 0.
- (Withdrawn) The compound as claimed in claim 11 wherein each of p, r, and s is
- (Withdrawn) The compound as claimed in claim 11 wherein p and s are 0 and r is
- 15. (Previously Presented) The compound as claimed in claim 1 wherein R<sub>2</sub> is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.

- (Previously Presented) The compound as claimed in claim 1 wherein R<sub>2</sub> is optionally substituted phenyl.
- (Withdrawn) The compound as claimed in claim 1 wherein R<sub>2</sub> is a carboxamide radical of formula -CONR<sup>B</sup>(Alk)<sub>n</sub>R<sup>A</sup> wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical.

n is 0 or 1,

RB is hydrogen or a C1-C6 alkyl or C2-C6 alkenyl group,

RA is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R<sup>A</sup> and R<sup>B</sup> taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

18. (Withdrawn) The compound as claimed claim 17 wherein

Alk is an optionally substituted –CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, CH<sub>2</sub>CH=CH-, or –CH<sub>2</sub>CCCH<sub>2</sub>- radical.

n is 0 or 1,

R<sup>B</sup> is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

R<sup>A</sup> is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4 methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or Nmorpholinyl,

- or R<sup>A</sup> and R<sup>B</sup> taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring.
- (Withdrawn) The compound as claimed in claim 17 wherein n is 0, R<sup>B</sup> is hydrogen and R<sup>A</sup> is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.
- (Withdrawn) The compound as claimed in claim 1 wherein R<sub>3</sub> is hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, or hydroxyethyl.
- 21. (Withdrawn) The compound as claimed in claim 1 wherein  $R_3$  is a carboxamide group -CONR<sup>B</sup>(Alk)<sub>n</sub>R<sup>A</sup> wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1.

RB is hydrogen or a C1-C6 alkyl or C2-C6 alkenyl group,

RA is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R<sup>A</sup> and R<sup>B</sup> taken together with the nitrogen to which they are attached form an Nheterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

22. (Withdrawn - Currently Amended) A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (IE) as defined in claim 1, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.

23. (Withdrawn - Currently Amended) The method as claimed claim <u>22</u>2+ for immunosuppression or the treatment of cancer; viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.

## 24. (Canceled)

25. (Previously Presented) A pharmaceutical or veterinary composition comprising a compound as defined in claim 1, or a salt hydrate or solvate thereof, together with a pharmaceutically or veterinarily acceptable carrier.